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Treatment of Patients Who Have
Fibrodysplasia Ossificans Progressiva
With Isotretinoin
MichaelA. Zasloff, MD, PhD*,**; DavidM. Rocke, PhDt,.
Leslie J. Crofford, MD*; Gregory ~ Hahn, MD**;
and Frederick S. Kaplan, MD**
the study. Only one of the 88 anatomic regions
that was completely uninvolved at the begin-
ning of the study became involved during
isotretinoin therapy. However, 16 of the 21 pa-
tients (76%) had major flare ups develop in 38
of 143 (27%) previously involved anatomic re-
gions while administered isotretinoin therapy.
Isotretinoin at steady state doses of 1 to 2
mg/kg per day decreased the incidence of het-
erotopic ossification at uninvolved anatomic
regions compared with an external control
group, as long as the medication was started
before the appearance of any orthotopic or
heterotopic ossification in that anatomic re-
gion. The data did not allow the determination
of whether isotretinoin was effective or detri-
mental in preventing disease flareups in re-
gions that had even minimal orthotopic or het-
erotopic ossification at the time the therapy
began. Extreme caution should be exercised
when using this medication in patients who
have fibrodysplasia ossificans progressiva.
Retinoids are a plausible family of therapeutic
agents for fibrodysplasia ossificans progressiva
due to their ability to inhibit differentiation of
mesenchymal tissue into cartilage and bone. A
prospective study was conducted to assess the
efficacy of isotretinoin (13-cis-retinoic acid) in
the prevention of heterotopic ossification in
patients who had fibrodysplasia ossificans pro-
gressiva. Eleven anatomic regions were as-
sessed in each of 21 patients by clinical exami-
~adiographs. and bone
~
if there was clinical, radiographic, or radionu-
elide evidence of orthotopic or heterotopic os-
sification anywhere in the region. There were
143 involved anatomic regions and 88 unin-
volved anatomic regions at the beginning of
The phenotype and natural history of tibrodys-
plasia ossiticans progressiva have been well
detined.4.7.9.10.24-26.36.37.40-43 Retinoids are a
plausible family of therapeutic agents for fi-
brodysplasia ossificans progressiva, princi-
pally because of their ability to inhibit differen-
tiation of mesenchymal tissue into cartilage
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and bone and their ability to alter the response
of skeletal precursor cells to growth fac-
tors.z°.38.45.49 Specifically, high doses of vitamin
A cause limb malformations in the murine em-
bryo by inhibiting the differentiation of limb
mesenchyme.z7.32 Vitamin A also inhibits the
differentiation of murine limb mesenchymal
cells in culture, thus, effectively preventing
chondrogenesis.32 DeSimone and Reddi 13 have
shown that retinoic acid and 13-cis-retinoic
acid significantly reduced mesenchymal cell
proliferation, endothelial cell proliferation, and
differentiation of chondrogenic progenitor
cells when administered during the prolifera-
tive phase of matrix induced endochondral
bone formation in the rat. It has been shown re-
cently that the combination of retinoic acid and
bone morphogenetic protein (BMP) 4 syner-
gistically induces apoptosis.20
The natural retinol vitamin A is stored in the
liver over a wide range of intake and is toxic at
high doses.z7.39 In contrast, the synthetic vita-
min A derivative 13-cis-retinoic acid
(isotretinoin, Roche Dermatologics, Nutley,
NJ) is not effectively stored by the liver and is,
.vitamin A for human
prevention of new heterotopic lesions in patients
who had fibrodysplasia ossificans progressiva. After
nearly 1 year of attempted recruitment, it was im-
possible to assemble an internal age matched and
disease severity matched control group. Most pa-
tients older than 20 years of age had severe manifes-
tations of fibrodysplasia ossificans progressiva and
did not wish to receive isotretinoin. Most patients
younger than 20 years of age had more mild mani-
festations of fibrodysplasia ossificans progressiva
and did not wish to receive a placebo. In addition,
the extreme paucity of patients who had fibrodys-
plasia ossificans progressiva made it impractical to
assemble an internal age matched and disease sever-
ity matched control group. The decision was made,
therefore, to use the data from the age controlled
and disease severity controlled external control
group on fibrodysplasia ossificans progressivaJ.36
This external control group had been assembled in
part to provide a valuable external baseline to evalu-
ate potential new therapies when conditions in this
extremely rare disease did not permit the use of a
true randomized controlled trial}6
Twenty-one patients who had fibrodysplasia
ossificans progressiva were recruited sequentially
between January 1984 and December 1988, dur-
ing an initial visit or followup visit to the fl-
brodysplasia ossificans progressiva clinic at
the National
isfied stringent diagnostic criteria for
pi asia ossificans progressiva. that
congenital malformation of the great toes
progressive heterotopic ossification of soft
sues. ..
ment for fibrodysplasia ossificans
the authors did not consider intercurrent
other medications (such as nonsteroidal
tlammatory medications or
criteria for exclusion. Contraindications to
use of isotretinoin during pregnancy were
viewed with all teenaged girls as required.
been used widely for the treatment of several
derrnatologiclS.33 and neoplastic6.28.29.48 disor-
ders, and is the most effective agent for the
treatment of cystic acne}2.31.33.44 Extensive data
in humans show that toxicity of chronic admin-
istration of this drug is minimal and principally
related to effects on the skin and mucous mem-
branes,13.33 although paradoxical intramembra-
nous hyperostosis has been noted at orthotopic
and heterotopic sites.S.14.16.17,23.34
On the basis of these preliminary find-
ings, the authors conducted a prospective
study to assess the safety and efficacy of 13-
cis-retinoic acid in the prevention of new
heterotopic lesions in patients who had fi-
brodysplasia ossificans progressiva.
Twenty
jstudy d
uary 19
There w
lation}O
A detailed history was obtained and
examination was performed on each patient at the
beginning of the study. Radionuclide bone scan~
were performed on each .
try into the study. at yearly intervals during
study.
tal survey
MATERIALS AND METHODS
An age matched internal control study was designed
to detennine the effectiveness of isotretinoin in the
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the study, and at the conclusion of the study. Pa-
tients were contacted in person, by telephone, or
by mail as many as 6 years after termination of
the study, and asked to complete a brief question-
naire about the subsequent course of fibrodyspla-
sia ossificans progressiva flareups.
For the purposes of this study, the investiga-
tors defined an anatomic region as that area typi-
cally represented by any of the following
domains on clinical, radiographic, or radionu-
clide bone scan: the cervical spine, thoracolum-
bar spine, right shoulder, left shoulder, right
elbow, left elbow, right hip, left hip, right knee,
left knee, and jaw. The authors considered an
anatomic region to be involved with fibrodyspla-
sia ossificans progressiva if there was any clini-
cal, radiographic, or radionuclide evidence of
orthotopic or heterotopic ossification anywhere
in that region. Conversely, a joint was considered
to be uninvolved only if all three modes of evalu-
ation (clinical examination, radiographic evalua-
tion, and radionuclide bone scan) showed no
evidence of orthotopic or heterotopic ossification
in that region. A complete blood count, plasma
transaminase levels, and plasma triglyceride lev-
els were obtained on each patient at entry into the
study, at 6-month intervals during the study, and
at the conclusion of the study.
Patients who entered the study were treated
with a single bedtime oral dose of isotretinoin at a
concentration of 1 mgikg per day. The dose was
raised by I mg/kg per day for 2-week intervals
until a final dose of 5 to 8 mg/kg per day was
reached. The medication dosage was adjusted
downward if side effects of cheilitis, xerosis, hair
loss, dry nasal mucosa, or dry mouth developed
in the patient.
Data on regional involvement were collated
from the studies in each patient and from the ex-
ternal control study on fibrodysplasia ossificans
progressiva!.36 A multivariate survival model
; fit to the data using software developed
specifically for this purpose.J.II.J9.46.47 Assessment
of statistical significance was calculated using the
robust variance approach.46
RESULTS
Twentv-one patients were enrolled in the
o;(udy during the 5-year period between Jan-
uary 1984 and December 1988 (Table I).
There were 13 males and eight females rang-
rrent use
lidal
lions to
.;y
equired,
olnd
Ie bone
.: time of en-
Is
of entry
ing in age from 3 years to 21 years of age
(median age, 14 years). The duration of
treatment ranged from 4 months to 10 years
(median duration, 3 years). The steady state
dose of isotretinoin varied from 0.5 mg/kg
per day to 8 mg/kg per day; (median steady
state dose, 1.7 mg/kg per day). Seventeen of
the 21 patients (81%) completed at least 1
year of therapy with isotretinoin, and 11 of
the 21 patients (52%) completed a full 3
years of therapy with isotretinoin. Eight of
the 21 patients (38%) elected to continue
treatment for longer than 3 years.
Ten (48%) of the 21 patients received in-
tercurrent treatment with an oral nons-
teroidal antiinflammatory medication. Eight
(38%) of the 21 patients received intercur-
rent treatment with oral etidronate at doses
of between 4 mg/kg per day and 20 mg/kg
per day (median dose of etidronate = 10
mg/kg per day.) Fourteen (67%) of the 21 pa-
tients received a nonsteroidal antiinflamma-
tory medication or etidronate or both. Seven
of the 21 patients (33%) received neither
nonsteroidal antiinflammatory medications
nor etidronate.
Eleven anatomic regions were assessed in
21 patients for a total of 231 anatomic re-
gionS (Table 2)... One hundred forty--three
anatomic regions were involved with ortho-
topic or heterotopic bone at the beginning of
the study. One hundred forty-four anatomic
regions were involved with orthotopic or het-
erotopic bone at the end of the study. There
were 88 uninvolved anatomic regions at the
beginning of the study, and 87 uninvolved
anatomic regions at the conclusion of the
study. Only one anatomic region that was
completely uninvolved at the beginning of
the study became involved during the course
of the study because of an episode of blunt
trauma to the left knee (Table 2; Patient 11).
Heterotopic ossification developed rapidly in
the patient at the site of trauma, and this pa-
tient was the only one in the study who sus-
tained heterotopic ossification in a region
that had been completely uninvolved at the
time that isotretinoin therapy was begun.
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TABLE 1. Isotretinoin Dosage Data: Adverse Reactions and Intercurrent
Medications
Steady State
Dose of
Isotretinoin
(mg kg/day)
Adverse
Reactions
From
Isotretinoin
Gender;
Age
at Entry
(years)
Intercurrent
Medications
Duration
of
Treatment
(years)
Patient
Number
O,T,M
O,T
O,M
Indomethacin
Aspirin
Etidronate
0.5
8.0
1.7
0.8
1.0
5.0
1.0
4.0
1.5
4.0
1.6
5.0
0.8
5.0
2.7
1.0
5.0
4.5
0.8
1.2
4.0
Male;4
Male;6
Male;12
Male;11
Male;18
Female; 14
Male;1?
Male;?
Female;16
Female;3
Male;6
Male;3
Male;21
Male;8
Male;21
Female;19
Female;15
Male;16
Female;21
Female;16
Female;5
10
5
5
1
2
0.3
3
2
4
3
3
5
0.5
0.5
2
0.3
5
1
5
1.5
5
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
0
D
D,T,M
T,M
D,M
D
Indomethacin and etidronate
Etidronate
Indomethacin
Etidronate
Indomethacin and Etidronate
Indomethacin
Etidronate
IndomethacinD,T
D,M
D
D,T,M
'I
'; C i :' :,.' 
::1
Indomethacin and etidronate
Indomethacin and etidronate
Indomethacin
-
D
~
D = dryness/cheilitis; T = transient elevations in triglycerides; M = metaphyseal bands/growth arrest lines
:~~~""
~
the skin and cheilitis. These side el
cUffed in 13 of21 patients (62%) an<l
lowering the dose of isotretinoin or
uation of therapy. Transient.
-
the 21 patients (29%). Dense
of the 21 patients (33%) after 1
apy. The metaphyseal bands disappeared
a lowering of the isotretinoin dose to be
mg/kg per day. Plasma transaminase
..
One child (Table I; Patient 21) sustained a
traumatic fracture of the left proximal
humerus while receiving a steady state dose ,
of isotretinoin of 4 mg/kg per day. The frac- -'
tore healed uneventfully within 6 weeks after
nonoperative treatment. There was no evi-
dence of posttraumatic heterotopic ossifica-
occurred at 38 of the 143 previously in-
volved regions (27%) in 16 of the 21 patients
(76%). Disease flareups during isotretinoin
therapy were substantiated by clinical exam-
ination, radiographic assessment and ra-
dionuclide bone scan evaluation. There did
not seem to be any important difference dur-
ing or after isotretinoin therapy in the fre-
quency of flareups in previously involved re-
gions; however, the data did not allow
testing of this hypothesis specifically. None
of the patients thought that the isotretinoin
was responsible for disease flareups during
treatment, nor did there seem to be any in-
creased frequency of immediate posttreat-
ment flareups.
High dose isotretinoin therapy (3-8 mg/kg
per day) produced a high incidence of mild
adverse reactions. The most common side ef-
I
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tion. Periosteal hyperostosis was not noted in
any of the patients, but might have been diffi-
cult to assess.
Among the 11 patients who were able to
complete 3 or more years of isotretinoin ther-
apy, steady state doses ranged from 0.5 mg/kg
per day to 8 mg/kg per day (median, 1.7
mg/kg per day). In the 11 patients who re-
ceived medication for 3 years or more, there
was no significant difference in the rate of
new heterotopic ossification between those
who received more than 1.7 mg/kg per day of
isotretinoin and those who received less than
1.7 mg/kg per day of isotretinoin. Also, there
was no significant difference in the rate of
new heterotopic ossification between those 14
patients who received intercurrent treatment
with nonsteroidal antiinflammatory medica-
tions or etidronate and those seven patients
who received only isotretinoin. However, the
very small sample sizes mean that differences
may have existed that could not be detected
with the present data.
The relative risk of heterotopic ossifica-
tion in a previously uninvolved anatomic re-
gion for those treated with isotretinoin was
0.117 corresponding to a reduction in risk of
88% (95% confidence interval: 0.008-0.497;
50% reduction to 99% reduction), compared
with a relative risJ< of 1.00 for those patients
in the external control group (p = 0.0013).
i
,tidronate
DISCUSSION
The data suggest hat oral isotretinoin therapy
may have inhibited heterotopic ossification in
completely uninvolved anatomic regions in
patients who had fibrodysplasia ossificans
~tidronate
etidronate
etidronate TABLE 2. Involvement of Sites With Heterotopic Ossification in 21 Patients With
Fibrodysplasia Ossificans Progressiva
Cervical
Spine;
Thoracolumbar
Spine; Jaw
Elbow
(right; left)
Hip
(right; left)
Knee
(right; left)
Shoulder
(right; left)
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;, .Wlitiailnvolvement of site; -= initial noninvolvement of site; e = exacerbation of involvement at a previously involved site;
9. new Involvement of previously uninvolved site.
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t
progressiva. The authors have no evidence as
to whether isotretinoin changed the risk of
heterotopic ossification in anatomic regions
that were even minimally involved with or-
thotopic or heterotopic bone at the time ther-
apy was instituted. Although isotretinoin
seemed to have some limited use in the pre-
vention of spontaneous heterotopic ossifica-
tion in patients who had fibrodysplasia ossifi-
cans progressiva, it had no apparent benefit in
the prevention of heterotopic ossification af-
ter surgery in those patients.12 Furthermore, it
is doubtful that isotretinoin had any effect in
the prevention of heterotopic ossification af-
ter soft tissue trauma.
Most of the patients who received isotreti-
noin already had experienced ossification of
the cervical spine, thoracolumbar spine, and
upper limbs, and there was no benefit of ther-
apy in those regions. If there was a beneficial
regional effect of isotretinoin therapy, it was in
the lower limbs (especially at the hips and
knees), because those anatomic regions were
less likely to be affected with orthotopic or het-
erotopic ossification at a young age when
isotretinoin therapy was instituted. Despite the
~tentialbenefits of isotretinoin, it was clearly
not a panacea for fibrodysplasia ossificans pro-
gressiva, because 16 of the 21 patients (76%)
had major flareups of previously involved ar-
eas develop while administered isotretinoin
therapy. Although these flareups were likely at-
tributable to the natural history of the disease,
the authors cannot exclude the possibility of a
paradoxical stimulation of orthotopic or het-
erotopic ossification in regions already af-
flicted with those processes.5,15.16.17.23,34
The temporal and spatial progression of
lesions in patients who have fibrodysplasia
ossificans progressiva follows patterns simi-
lar to those seen during normal skeletal em-
bryogenesis.' ,26,42 The molecular basis of this
sequential involvement is unknown but may
involve the secretion of diffusible morphogens
that establish the tissue specific patterns of
gene expression.42 Retinoids profoundly affect
morphogenetic gradients and can induce and
inhibit gene expression,18,35,38.45,48.49 Retinoids
in combination with BMP 4 synergistically in-
duce apoptosis}O It is clear, for example, that
the retinoids have different effects on primi-
tive mesenchymal tissue and on differentiated
chondroosseous tissue.13.38,45,49 It is possible
that these developmental differences in sus-
ceptibility to retinoid exposure could underlie
the observed findings of isotretinoin therapy
on patterns of orthotopic and heterotopic ossi-
fication in patients who have fibrodysplasia
ossificans progressiva.
Despite the demonstration of some poten-
tial benefits of isotretinoin, there were sev-
eral major shortcomings of the study. First,
there was no comparable internal control
group. Such a control group was virtually
impossible to assemble considering the rar-
ity of the disease, and the unwillingness of
patients to participate in a controlled ran-
domized study. It is doubtful that a random-
ized study could ever be performed in this
group of patients.3,21
Second, there were several ways in which
the data from this study were not exactly com-
parable with the data in the external control
group.7,36 In this study, regional anatomic in-
volvement was assessed
ographic, and radionuclide bone scan evalua~""
tion. In the external control group, regional
anatomic involvement was assessed from pa-
tient questionnaires and clinical data alone.
These differences in the methods of assess-
ment resulted in a different definition of an in-
volved anatomic region. This had two effects.
First, because the definition
was more sensitive in this study, the
were biased against the effectiveness
isotretinoin. Thus, a significant difference
would have been harder to achieve, but
should have been believable if it had oc-
curred. Second, a patient would tend to have
fewer anatomic regions at risk for future in-
volvement under the criteria used in this study
than under the criteria used in the external
control survey; however, this produced no
known bias in favor of isotretinoin effective-
ness. Despite these limitations, the control
population represented the most valid exter-
~
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tretinoin between I and 2 mg/kg per day was
sufficient to achieve the observable effects
while also minimizing the risk of unpleasant
side effects.
Fourth, patients in this study were treated
for variable lengths of time. Some were un-
able to tolerate the side effects of the high
dose medication, and stopped the medication
early in the course of the protocol. Others
who experienced major disease flareups
while taking the isotretinoin, became dis-
couraged and stopped the medication. Still
others tolerated the isotretinoin, and elected
to continue the medication indefinitely.
Thus, the study may have inadvertently self
selected for patients who responded more fa-
vorably to isotretinoin.
If isotretinoin therapy is considered, the
authors recommend that the total daily
steady state dose not exceed 2 mg/kg per
day. Patients must be apprised fully of the
potential side effects of treatment. Clinical
symptoms, plasma triglyceride, and transam-
inase levels should be monitored.
To date, no modality (including iso-
tretinoin) used in the prevention or treatment
of fibrodysplasia ossificans progiessiva has
proven to be fully effective in changing the
inexorable natural history of the condition.2
Any enthusiasm that may exist for the use of
isotretinoin in the treatment of patients who
have fibrodysplasia ossificans progressiva
must be tempered even further by the stark
realization that the study was flawed by an
imperfect control group, and that under the
best of circumstances isotretinoin is not a
panacea. Nevertheless, the limited benefits
derived from isotretinoin therapy have re-
vealed an option for treating some patients
who have fibrodysplasia ossificans progres-
siva. The authors think that the search for a
molecular cause for fibrodysplasia ossificans
progressiva will le:lo to much more fruitful
therapies.8.4o.-I2
ys in which
:<actly com-
mal control
,matomic in-:linical,.scan 
evaiua-
.up,
,ed ~
data
,s of
nal control group that the authors could as-
semble for assessment of the clinical efficacy
of isotretinoin.
Bailar et al,3 have provided a detailed
guideline for interpreting the value of studies
without internal controls: "Sometimes ques-
tions of clinical interest can be addressed
only by investigations without internal con-
trols. Such studies nearly always make use of
other types of comparisons (external con-
trols) such as historical controls. These stud-
ies have a small but important and unique
role in clinical investigation."
Bailar and colleagues described five semi-
nal features that added to the strength and
clinical value of such studies: "I. An intent by
the investigator expressed before the study
that the treatment will affect the outcomes re-
ported. 2. Planning of the analysis before the
data are generated. 3. Articulation of a plausi-
ble hypothesis before the results are observed.
4. A likelihood that the results would have
been of interest even if they had been oppo-
site. 5. Reasonable grounds for generalizing
the results from the study subjects to a
broader group of patients. In spite of potential
pitfalls, carefully selected and reported stud:'
ies without internal controls can playa sub-
stantial part in the acquisition of scientific
knowledge."3 Each of the five criteria for a
valid external control group described by
Bailar et al were met by this study.
Third, there were major differences in the
steady state medication dosages throughout
the study because many patients could not
tolerate the unpleasant side effects of chronic
high dose (5-8 mg/kg per day) isotretinoin
therapy. Therefore, the dose of medication
was reduced to the highest level tolerable in
each patient. Despite the wide range of
steady state medication dosages, there
seemed to be no important difference in the
inhibition of new heterotopic lesions in pre-
\ luusly uninvolved regions between patients
who received less than the median dose of
1.7 mg per day, and those who received more
than that amount of medication. The data
therefore suggested that a dose of iso-
/, the
.;tiveness
It -.
achieve,
f it had
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for future
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produced
om
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